The ovarian cancer therapy market retains its potential for commercial reward for drug developers. Although the disease tends to respond well initially to chemotherapy and current drug treatment relies heavily on chemotherapy agents, experts are increasingly looking to targeted therapy to improve treatment outcomes. As such, substantial opportunity exists for therapies able to augment or replace the efficacy of chemotherapy. Despite the anticipated entry of several novel therapies during the forecast period, major areas of unmet need will remain, including treatments for first-line advanced disease and for platinum-resistant disease.

Questions Answered in This Report:

  • We anticipate the ovarian cancer market will more than double in size over the forecast period. What factors are set to drive market growth? Will anything constrain the ovarian cancer market? What challenges and opportunities remain?

  • Following the approval of bevacizumab (Roche/Genentech/Chugai’s Avastin) for ovarian cancer in all the markets under study, the angiogenesis inhibitor drug class is set to grow through 2024. What will fuel the growth of the angiogenesis inhibitor drug class? Are any other angiogenesis inhibitors expected to launch? How will entry of biosimilar bevacizumab impact this drug class?

  • In late 2014, the first biomarker-associated therapy, olaparib (AstraZeneca’s Lynparza), was approved for ovarian cancer in the United States and Europe. How will olaparib be received in different markets based on its differing approvals? What other PARP inhibitors are set to launch? What is the size of the population eligible for PARP inhibitors? What sales will the PARP inhibitor drug class realize?

  • MEK inhibition of LGSOC has emerged as a potential therapeutic target. How many MEK inhibitors are in development for ovarian cancer? What sales can this drug class expect?

  • Drug treatment of ovarian cancer remains centred around chemotherapy, leaving unmet need opportunities for drug development. What are the major areas of unmet need in ovarian cancer? Which areas may provide the highest commercial rewards? How are companies approaching drug development in ovarian cancer?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts; physician surveys fielded to approximately 30 physicians from each of the major markets who treat at least five ovarian cancer patients per month.

Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).

Population segments in market forecast: Early-stage first-line, advanced-stage first-line, second-line platinum-sensitive, second-line platinum-resistant, third-line, fourth and subsequent lines.

Market forecast features: Using a proprietary patient-flow model incorporating mortality, we forecast population sizes and drug sales for all patient segments through 2024.

Author(s): Jennifer Bamford, B.Sc.
Amy Duval, M.Res.

Related Reports

Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PA...

View Details

Ovarian Cancer | Disease Landscape and Forecast | G7 | 2020

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inh...

View Details

Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)

The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncolo...

View Details

Ovarian Cancer - Epidemiology - Mature Markets

DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We...

View Details